The London-based business – which launched in 2021 – will use the funds to further its research, expand its team and continue on its mission to create new drugs and medicines using AI.

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google's DeepMind in 2021, has raised external capital ...

Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical ...

Isomorphic Labs raised $600 million in its first external funding round, led by Thrive Capital with participation from GV and ...

Isomorphic Labs raised $600 million in its first external funding round to boost its artificial-intelligence drug design pipeline across multiple therapeutic areas. The 4-year-old subsidiary of Google ...

AlphaFold 3, the improved version of the model used by Isomorphic Labs’ drug design engine, debuted last May. It can predict the shape of not only proteins but also DNA, RNA and other biological ...

While Isomorphic is an independent unit of Google parent Alphabet, Hassabis' dual roles reflect the intertwined relationship between the two parties. Isomorphic has never revealed how much Google ...

Alphabet spinoff SandboxAQ — an AI and quantum computing startup — added another $150 million to its Series E from the likes ...

as well as Alphabet. Isomorphic's technology platform has already generated a number of AI models that are being applied to the discovery of new medicines, and it already counts Eli Lilly and ...

It will receive follow-on capital from existing backer Alphabet. The London-based company’s goal is an ambitious one – to “solve all disease,” according to the Isomorphic Labs site.